Results 101 to 110 of about 20,176 (178)

Effect of Once-Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants. [PDF]

J Clin Pharmacol
Csonka D, Gargano C, Goyal N, De Meulder M, Yartsev V, Ruixo JJP.   +5 more
europepmc   +1 more source

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol. [PDF]

J Clin Pharmacol
Cronenberger C, Amin NB, Le VH, Carvajal-Gonzalez S, Ashworth AL, Yi EC, Schuster T, Zhang Y, Frederich RC, Friedman GS, Wang EQ, Tsamandouras N.   +11 more
europepmc   +1 more source

Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk. [PDF]

Trials
Nyein PP, Haskelberg H, Martinello M, Lowe M, Goodman-Meza D, Avihingsanon A, Kelleher AD, Rodgers A, Schutte AE, Nnakelu EC, Byakwaga H, Trevillyan J, Losso M, Kumarasamy N, Azwa RISR, Kaplan R, Clifton B, Arnott C, Dharan NJ, Petoumenos K, Matthews GV.   +20 more
europepmc   +1 more source

A hierarchical risk assessment framework for head-to-head comparison of statin safety profiles in Chinese patients. [PDF]

Sci Rep
Tsui L, Wang D, Fan C, Shi C.
europepmc   +1 more source

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. [PDF]

Circulation
Vega RB, O'Mahony G, Barbour AM, Yu H, Knöchel J, Brengdahl J, Hochdörfer T, Bergenholm L, Töppner Carlsson E, Ahnmark A, Underwood CR, Rudvik A, Carter D, Laru J, Gutgsell A, Twaddle L, Garkaviy P, Bogstedt A, Hurt-Camejo E, Miliotis T, Ryaboshapkina M, Hober A, Hubbard B, Serrano-Wu M, Kaushik V, Geschwindner S, McCarthy MC, Lindén D, Rosenmeier JB.   +28 more
europepmc   +1 more source

ABCG2 Genetic Variability in Drug Exposure and Toxicity: Implications for Clinical Practice. [PDF]

Toxics
Božina T, Šimičević L, Ganoci L, Lovrić M, Klarica Domjanović I, Trkulja V, Božina N.   +6 more
europepmc   +1 more source

Pragmatic trial assessing polygenic risk driven statin therapy for cardiovascular disease prevention: study protocol for the EE-PRS trial. [PDF]

BMJ Open
Voit A, Elken A, Viigimaa M, Kalda R, Fischer K, Toompere K, Irs A, Milani L, Alavere H, Pajusalu S, Org E, Alloja J, Kaarna K, Jürisson M.   +13 more
europepmc   +1 more source

Safety and efficacy of triple combination therapy in hypertension and dyslipidemia: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Egypt Heart J
Shaban AY, Hassan A, Eltawansy S, Hassan MA, Desouki MT, Ahmed N, Badr S, Elgendy AY, Nassar M, Hakim D.   +9 more
europepmc   +1 more source

Evolocumab Alters Transcriptomic Signatures and Identifies Inflammatory Biomarkers in Brain-Heart Syndrome with Coronary Heart Disease History. [PDF]

Int J Gen Med
Dong H, Gong X, Zhao Z, Joyama Y, Ji X, Qu P.   +5 more
europepmc   +1 more source